Bendamustine Plus Rituximab Versus CHOP Plus Rituximab in the First-Line-Treatment of Patients with Follicular, Indolent and Mantle Cell Lymphomas: Results of a Randomized Phase III Study of the Study Group Indolent Lymphomas (StiL)

Mathias Rummel(Universitätsklinikum Gießen und Marburg), Wolfram Brugger(University of Freiburg), Ulrich von Gruenhagen(Praxis für Hämatologie und Onkologie), Ulrich Kaiser(University of Applied Sciences Landshut), Dorothea Kofahl-Krause(Medizinische Hochschule Hannover), N. Niederle(Klinikum Leverkusen), Harald Balló(Praxis für Hämatologie und Onkologie), Eckhart Weidmann(Krankenhaus Nordwest), Manfred Welslau(Klinikum Aschaffenburg), Gerhard Heil(Goethe University Frankfurt), Wolfgang Knauf(Krankenhaus Bethanien), Martina Stauch, Heinz A. Duerk, Christina Balser(Philipps University of Marburg)
Blood
November 16, 2008
10.1182/blood.v112.11.2596.2596
Cited by 37

Related Papers

FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial
|The Lancet|2013|1.5k
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML
|Blood|2010|485
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia
|New England Journal of Medicine|2010|425
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial
|The Lancet Oncology|2016|417